
EU Health Union ignoring cardiology
While the EU has already presented rules to establish a European Health Data Space (EHDS) and Europe’s Plan against Cancer within its Medicines...

Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...

Healthcare investments in Catalonia at record high
According to the 2021 BioRegion of Catalonia Report, the medical technology sector attracted most of the money, fueled by two large operations....

ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

New partnerships push InDevR for Series B financing
Investments into InDevR, Inc. came from New York-based Adjuvant Capital ($4m) and French bioMèrieux SA ($5m), which will enable the commercial...

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

Benefits of booster campaigns questionable
While Pfizer Inc and BioNTech SE financial outlooks in February prognosed more than $50bn in combined coronavirus disease (COVID-19) vaccine sales in...